However, due to the highly heterogeneous nature of glioblastoma, characterized by variations in immune features and treatment responses among individuals, further in-depth experimental and clinical research is required to ascertain the precise role of CD33 in GBM. The gene discussed is CD33; the disease is glioblastoma.